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Background: We sought to develop and externally validate a nomogram and web-based calculator to individually predict
the development of serious complications in seemingly stable adult patients with solid tumours and episodes of febrile
neutropenia (FN).
Patients and methods: The data from the FINITE study (n¼ 1133) and University of Salamanca Hospital (USH) FN registry (n¼ 296)
were used to develop and validate this tool. The main eligibility criterion was the presence of apparent clinical stability, defined as
events without acute organ dysfunction, abnormal vital signs, or major infections. Discriminatory ability was measured as the
concordance index and stratification into risk groups.
Results: The rate of infection-related complications in the FINITE and USH series was 13.4% and 18.6%, respectively. The
nomogram used the following covariates: Eastern Cooperative Group (ECOG) Performance Status X2, chronic obstructive
pulmonary disease, chronic cardiovascular disease, mucositis of grade X2 (National Cancer Institute Common Toxicity Criteria),
monocytes o200/mm3, and stress-induced hyperglycaemia. The nomogram predictions appeared to be well calibrated in both
data sets (Hosmer–Lemeshow test, P40.1). The concordance index was 0.855 and 0.831 in each series. Risk group stratification
revealed a significant distinction in the proportion of complications. With a X116-point cutoff, the nomogram yielded the
following prognostic indices in the USH registry validation series: 66% sensitivity, 83% specificity, 3.88 positive likelihood ratio, 48%
positive predictive value, and 91% negative predictive value.
Conclusions: We have developed and externally validated a nomogram and web calculator to predict serious complications that
can potentially impact decision-making in patients with seemingly stable FN.
Over the years, in-patient intravenous antibiotic treatment has
been demonstrated to be the most effective strategy for patients
with postchemotherapy febrile neutropenia (FN). More recently,
patients with solid tumours have been seen to present mild
episodes associated with clinical stability, particularly when they
receive care in the early stages of infection (Carmona-Bayonas
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et al, 2011); hence, not all of them require prolonged hospitalisa-
tion for intravenous antibiotics. Consequently, various groups have
sought to stratify patients with FN into high- and low-risk groups,
in an attempt to individually predict their clinical course and
optimise treatment (Talcott et al, 1992; Klastersky et al, 2000; Ahn
et al, 2015; Carmona-Bayonas et al, 2015).
The Continuous Care Working Group of the Spanish Society of
Medical Oncology (SEOM, for its acronym in Spanish) has recently
devised a prognostic classification, called the Clinical Index of
Stable Febrile Neutropenia or CISNE, for patients with solid
tumours and seemingly stable episodes. CISNE is capable of
classifying stable patients according to their risk of serious
complications and death more accurately than previous scales
(Carmona-Bayonas et al, 2015).
CISNE is used in the same way as the eligibility criteria
of most randomised clinical trials that compared in-patient
treatment to ambulatory treatment or oral vs intravenous
antibiotics and that excluded patients using pragmatic clinical
criteria, such as shock, comorbidity, acute organ failure,
pneumonia, or oral intolerance (Teuffel et al, 2011; Vidal et al,
2013). These potentially serious situations comprise a starting
point for prognostic evaluation, as recommended by the
American Society of Clinical Oncology’s (ASCO) clinical practice
guideline (Flowers et al, 2013).
The CISNE model was designed as an adjuvant tool in decision-
making, allowing to individually predict the development of
serious complications despite the absence of evident risk criteria
such as those previously mentioned (Carmona-Bayonas et al,
2015). While CISNE’s prognostic potential has been demonstrated,
further applicability and efficacy evaluations are needed to
generalise its use in the community.
The aim of this study was to develop a nomogram and online
calculator capable of generating individualised predictions, and to
externally validate this new decision-making support tool to
predict serious complications in an independent series of the
University of Salamanca Hospital (USH) FN registry.
MATERIALS AND METHODS
Patients. The nomogram was developed from a prospective
cohort of 1133 patients with seemingly stable FN from the FINITE
(Evaluacio´n de Factores Prono´sticos en Fiebre Neutrope´nica,
Tumour So´lido y Episodios Estables) study. A description of the
FINITE study design, data collection, data quality, and eligibility
criteria have been reported previously (Carmona-Bayonas et al,
2015). Briefly put, FINITE was a multicentre study conducted in 22
Spanish centres and one Chilean centre between 2012 and 2014.
The key eligibility criteria required that the patient be adult, have a
solid tumour treated with mild–moderate intensity chemotherapy,
not be hospitalised for another reason, not have acute organ failure
(renal, cardiac, respiratory) or decompensation of chronic
insufficiency, lack septic shock or hypotension (systolic pressure
o90mmHg), have no severe infections, and lack other serious
complications within the first 3 h of being diagnosed with FN (see
definitions in Table 1).
Validation was carried out with the USH FN registry. The
University of Salamanca Hospital is a 900-plus bed tertiary
institution, and its Medical Oncology Department is the reference
department for an estimated population of 350 000 inhabitants. In
2010, this department launched a project to create a database of FN
patients. The objective of this registry was to understand the
epidemiological characteristics and outcomes after the centre had
instituted an ambulatory programme to manage these patients.
This registry has been reported previously by the authors (Matos
et al, 2014). The hospital’s Ethics Review Board approved the
registry and written informed consent was obtained from the
patients.
The criteria for entry into the registry included patients
(X18 years) with solid tumours or lymphomas treated with
chemotherapy who sought emergency medical care for fever
X38 1C and neutrophils p500/mm3 (or p1000/mm3 with an
expected decrease p500/mm3), regardless of their clinical status.
This registry took into account only the first episode suffered by a
patient during the study period.
Study design. The FINITE study design has been described
previously (Carmona-Bayonas et al, 2015). Insofar as the USH
registry is concerned, clinical data sources consisted of information
gleaned from both patient and Emergency Department records.
This registry was updated periodically by the on-duty oncologists
and the people charged with treating these patients. To standardise
collection, the USH investigators designed a form containing the
following variables: description of patients’ clinical status, includ-
ing vital signs, other medical comorbidities, tumour type and stage,
oncological treatment, FN management, microbiology, duration,
and outcome. Missing values for any CISNE explanatory model
covariates were disallowed, although all predictors were readily
available and there were no exclusions for this reason.
Patients in the USH registry were classified as seemingly
stable or unstable, as per the same criterion followed in the
CISNE-derived series (see Table 2). All individuals remained in
observation for at least 6 h. As per the treating physician’s
judgement, clinically stable patients were given the possibility of
receiving direct home care (discharge between 6 and 24 h), early
discharge (24–72 h), or standard admission (stay X72 h).
The primary end point for this analysis was the occurrence of
major FN-associated complications in patients believed to be
clinically stable. Major complications were defined as hypotension,
acute renal, respiratory, or cardiac failure, arrhythmia, major
bleeding, delirium, acute abdomen, disseminated intravascular
coagulation, and other events (Table 1).
To minimise subjectivity in data interpretation, two specialists
in patient support treatment from USH evaluated the presence of
complications and CISNE predictors separately, according to
detailed instructions and objective definitions of the variables
(Table 2). The investigators were not informed as to the CISNE
categories, despite the fact that data collection was not blinded.
Observation was a minimum of 7 days from the time of arrival
at the USH Emergency Department until the episode had fully
resolved. Resolution, in turn, was defined as the disappearance of
all signs of infection, recovery from neutropenia (X1500
neutrophils per mm3), and being afebrile for 48 h. In the event
that the patient was discharged early or received ambulatory
treatment, a home surveillance component was used to cover this
period.
Development of the nomogram and web-based calculator.
A nomogram is a graphic representation of the solution of an
equation that provides a reasonable approximation of the
probability of a particular outcome. The CISNE model explanatory
covariables consisted of: Eastern Cooperative Group (ECOG)
Performance Status X2, chronic obstructive pulmonary disease,
cardiovascular disease, mucositis NCI grade X2, monocytes
o200/mm3, and stress-induced hyperglycaemia (Carmona-
Bayonas et al, 2011). To build the nomogram, the models’
coefficients were updated and retrained, bearing in mind the entire
FINITE series (n¼ 1133). The objective definition of clinical
stability, issues regarding inferential generalisability, heterogeneity
concerning prevalence of the explanatory covariables, and the
model’s scope of application have been described previously
(Carmona-Bayonas et al, 2015). We used k-fold crossvalidation
with k¼ 5 to limit the risk of overfitting when obtaining the scores
associated with each of the nomogram’s covariates. We therefore
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conducted five logistic regression models adjusted using a
maximum-likelihood estimation to predict the binary outcome
(presence or absence of serious complications) on the training
subsets over five different random partitions of the data into five-
folds. These models’ coefficients served to construct five nomo-
grams. The goodness of fit for each nomogram was verified by
means of the Hosmer–Lemeshow test on each subset. Finally, we
averaged estimates of all nomogram parameters from the five
models to correct and assess the bias thereby generated. The final
nomogram (Figure 2) was used to assign a probability of
complication to each patient. The same was carried out to develop
an online calculator: http://www.iricom.es/prognostictools/Cisne/
inicio.aspx.
To determine the discrimination ability of the final model, we
developed 1000 bootstrap replications that were used as internal
validation subsets, calculating the model’s bias-corrected concor-
dance (c)-index to predict serious complications. To estimate the
optimal cutoff point of the model, predictions were dichotomised
by Youden’s J index (Youden, 1950).
External validation of the nomogram in the USH registry. All
patients from USH who met the criterion of clinical stability were
assessed using this nomogram (Ghanem et al, 2014). The
calibration and discriminatory ability were externally validated in
clinically stable patients from the USH registry. First, we used a
bootstrapping procedure with 2000 replications to get overfitting-
corrected estimates of predicted vs observed values to evaluate the
nomogram’s calibrations. The absolute mean and squared errors
and the 0.9 quantile of the absolute error were calculated. Then, we
computed a summary of the c-index of this validation subset as a
measure of discrimination. Based on previous research, around 300
patients would be sufficient for this analysis (Peduzzi et al, 1996).
All statistical analyses were performed using R software, including
the rms package version 4.2-1 (R Development Core Team, 2014;
Harrell et al, 2015).
RESULTS
Patients. Between the two registries, a total of 1952 patients with
FN were screened, of which 73% of the FINITE cohort (n¼ 1133)
and 76% of the USH registry (n¼ 296) were eligible for analysis.
Figure 1 is a flowchart of both databases. Table 2 presents the
descriptive statistics of each series. There are no differences
between both series with respect to age (median of 60 years in
both), functional status, and tumour stage. The distribution of
tumours and episodes is quite similar. The most remarkable
differences between the series lie in the fact that there was greater
prophylaxis with granulocyte-colony-stimulating factor (G-CSF) in
the FINITE cohort (27% vs 13%; Po0.001) and prior antibiotic use
(18% vs 5%; Po0.001). In contrast, the USH patients present a
higher rate of direct ambulatory care (30% vs 11%, Po0.0002) or
treatment with oral antibiotics (36% vs 10%, Po0.0002).
Outcomes. The multicentre FINITE series revealed marginally
lower rates of serious complications and mortality: 13.4% (95% CI,
11.5–15.5) and 1.8% (95% CI, 1.1–2.7), respectively. In compar-
ison, the rate of infection-related serious complications and death
in seemingly stable patients in the USH registry was 18.6% (95%
CI, 14.6–23.4) and 2.7% (95% CI, 1.3%–5.2%), respectively. In this
registry, the most common complications were shock (n¼ 22),
acute respiratory failure (n¼ 11), major bleeding (n¼ 5), and
cardiac insufficiency (n¼ 3). In the 108 USH patients who were
discharged early or directly, 5% (n¼ 6) were readmitted because of
complications. These complications were hypotension in two cases,
and respiratory failure, mucositis, anaemia, and intestinal occlu-
sion in one case each. None of the patients who were readmitted
died. In contrast, the death rate was significantly higher among the
ineligible USH patients (unstable): 18.1% (95% CI, 11.6–27).
Development of a nomogram based on the FINITE data
set. First, we developed the prognostic nomogram for estimating
Table 1. Key definitions of the study
Variable Definition
Clinical stability Within the first 3 h from the first assessment: (1) no acute organ failure (renal, cardiac, respiratory) or decompensation of chronic
insufficiency, (2) no septic shock or hypotension (systolic pressureo90mmHg), (3) no known severe infections (see below) and
(4) no other serious complications, included as admission criterion on their own (pulmonary thromboembolism, arrhythmias,
disseminated intravascular coagulation, and bleeding)
Major infections Pneumonia, empyema, peritonitis, cellulitis 45 cm, suspected typhlitis, enteritis NCI grade 3–4, appendicitis, cholecystitis or
other complicated abdominal infections, meningitis, encephalitis, endocarditis, and pyelonephritis
Hypotension Systolic blood pressure remaining at o90mmHg and calling for inotropes or aggressive fluid resuscitation
Acute respiratory failure (1) O2 saturation o90%, (2) partial pressure O2 in arterial blood o60mmHg, or (3) partial pressure of CO2 in arterial blood
X45mmHg
Acute renal failure (1) Increased creatinine by X0.3mgdl within 48 h, (2) increased creatinine to X1.5 times baseline in the previous 7 days,
or (3) urine volume o0.5ml kg1 per h for 6 h
Acute heart failure Abrupt onset of dyspnoea, pulmonary oedema, and O2 desaturation demanding emergency treatment
Arrhythmias Arrhythmias were deemed complications whenever they altered cardiovascular stability
Delirium Acute, fluctuating disturbance of mental status accompanied by cognitive impairment
Major bleeding (1) Associated with death, (2) in critical site (intracranial, intraspinal, intraocular, retroperitoneal, or pericardial); (3) associated
with decreased haemoglobin values by X2gdl1, or (4) bleeding requiring transfusion of two units of concentrated RBC
Acute abdomen Defined as a syndrome due to a variety of disease conditions requiring urgent medical or surgical management
COPD Emphysema, chronic bronchitis, decreased forced expiratory volumes, or need for O2 therapy, corticosteroids, or bronchodilators
Chronic cardiovascular disease Chronic conditions such as cor pulmonale, heart failure, cardiomyopathy, hypertensive heart disease, arrhythmias, valvular
heart disease, or other structural malformations, at risk of acute exacerbations in the context of FN. Single isolated episodes of
atrial fibrillation in the past are not included here as chronic cardiovascular diseases
(SIH) Glucose X121mgdl1 or X250mgm 2 in a diabetic patient (or in patient on steroid treatment)
Mucositis NCI grade X2 As a minimum, patchy ulcerations or pseudomembranes, or moderate pain with indication for modified diet
Abbreviations: COPD¼ chronic obstructive pulmonary disease; NCI¼National Cancer Institute; SIH¼ stress-induced hyperglycaemia.
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the risk of serious complications. Figure 2 illustrates this
nomogram. Actual proportions deviated by o1% from the
predictions (Figure 3). The Hosmer–Lemeshow test showed good
fit of the model for the entire series, and separately for each of the
five subsets used to create it. Youden’s J index corresponds to
X116 points (equivalent to a risk of serious complicationsX13%),
which is considered the optimal cutoff value for high risk. The
distribution of prognostic categories by nomogram scores is
presented in Table 3. Across the 1000 bootstrap replications, the
bootstrap optimism-corrected c-index for predicting serious
complications was 0.855 (95% CI, 0.823–0.887).
Validation of the nomogram in the USH registry. We then
applied the nomogram to the subgroup of 296 apparently stable
USH patients. Table 3 shows how the complications and mortality
rates go up as the nomogram score increases (Po0.001). With a
cutoff ofX116, the nomogram has 66% sensitivity, 83% specificity,
3.88 positive likelihood ratio, 0.41 negative likelihood ratio, 48%
positive predictive value, and 91% negative predictive value.
A c-index of 0.831 (95% CI, 0.782–0.871) was displayed, denoting
good discriminatory ability. The nomogram’s predictions appear to
be well calibrated compared with those observed in the USH
registry with a mean absolute error of 3.6% (Figure 4). The
Hosmer–Lemeshow goodness-of-fit test (w2 6.01; P¼ 0.3) also
exhibited appropriate calibration (Figure 4). Notably, in the
subgroup that was readmitted after direct or early discharge
(n¼ 6), 5 (83%) had a score X116 on the CISNE nomogram
(high risk).
DISCUSSION
This study describes the development of a nomogram to predict
prognosis in patients with seemingly stable FN. The criterion for
application of the CISNE nomogram is initial apparent clinical
stability as defined by the absence of serious complications,
extensive infection, shock, and acute organ failure at the time of
first evaluation. The nomogram assigns a predicted probability of
serious complications based on the CISNE model’s explanatory
covariables (ECOG PSX2, chronic obstructive pulmonary disease,
cardiovascular disease, mucositis NCI grade X2, monocytes
o200/mm3, and stress-induced hyperglycaemia). This nomogram
has been applied to an external validation series from a registry of
consecutive cases of FN at the USH. In this series, it has proven
reasonable calibration and good discriminatory ability to predict
serious complications.
Although the CISNE nomogram was designed chiefly to predict
the likelihood of serious complications in stable patients initiating
in-patient therapy, the USH data confirm that a two-stage
classification similar to that used in the FINITE study (exclusion
criteria plus the CISNE nomogram) comprise a safe method by
which to select low-risk patients when the screening takes place
within 6 to 24 h from the time of arrival at the Emergency
Department.
The USH series reveals that the absence of baseline criteria of
severity (apparent clinical stability) is efficacious when selecting
patients with relatively low risk of complications and death; for
Table 2. Comparison of baseline characteristics in the study cohorts
Characteristics FINITE series, n¼1133 (%) USH registry, n¼296 (%) P-value
Age (years), X65 411 (36%) 105 (35%) NS
Male gender 520 (45%) 127 (43%) NS
COPD 151 (13%) 27 (9%) NS
Chronic cardiovascular disease 86 (8%) 28 (9%) NS
ECOG PS X2 198 (17%) 44 (15%) NS
Mucositis NCI grade X2 207 (18%) 29 (10%) 0.0005
Monocytes o200/mm3 537 (47%) 126 (43%) NS
Stress-induced hyperglycaemia 351 (31%) 87 (29%) NS
Prophylactic G-CSF 302 (27%) 38 (13%) o0.0002
Previous antibiotics, o1 month 202 (18%) 16 (5%) o0.0002
Malignant disease
Breast cancer 391 (35%) 114 (39%) NS
Lung cancer 234 (21%) 61 (21%) NS
Oesophagus-gastric cancer 80 (7%) 16 (5%) NS
Colorectal cancer 59 (5%) 15 (5%) NS
Sarcoma 50 (4%) 17 (6%) NS
Germ-cell cancer 26 (2%) 9 (3%) NS
Other 293 (26%) 64 (22%) 0.0003
Tumour stage IV 517 (46%) 140 (47%) NS
Foci of infection
Enteritis 143 (13%) 27 (9%) NS
Respiratory tract 293 (26%) 76 (26%) NS
Urinary tract 67 (6%) 32 (11%) 0.003
Mucositis 132 (12%) 27 (9%) NS
No infectious focus 384 (34%) 124 (42%) 0.01
Other 114 (10%) 10 (3%) 0.0003
Patient management
Outpatient 122 (11%) 90 (30%) o0.0002
Early discharge 215 (19%) 21 (7%) o0.0002
In-patient 796 (70%) 185 (63%) 0.01
Initial route of antibiotics, oral 111 (10%) 106 (36%) o0.0002
Neutrophils o100/mm3 500 (44%) 68 (23%) o0.0002
Abbreviations: COPD¼ chronic obstructive pulmonary disease; ECOG PS¼Eastern Cooperative Oncology Group Performance Status; G-CSF¼granulocyte colony-stimulating factor;
MASCC¼Multinational Association for Supportive Care in Cancer; NCI¼National Cancer Institute; NS¼ nonsignificant.
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Patients assessed for eligibility (n = 1932) 
FINITE study
(n = 1543)  
Not meeting inclusion criteria (n = 350) 
♦ Pneumonia (n = 42) 
♦ Other serious infection (n = 27) 
♦ Shock (n = 121) 
♦ Acute organ failure (n = 45) 
♦ Exacerbated chronic dysfunction (n = 37) 
♦  Complications at the onset (n = 73) 
♦ Non-adherence to IDSA guidelines (n = 5) 
♦ Complications (n = 152) 
♦ Death (n = 20) 
Eligible episodes of
seemingly stable FN
(n = 1133)    
♦ Declined to participate (n = 15) 
♦ Missing values (n = 0) 
♦  In-patients (n = 16) 
♦ Multiple episodes for a single patient (n = 21) 
♦  Other reasons (n = 8) 
Not meeting inclusion criteria (n = 93) 
♦ Pneumonia (n = 1) 
♦ Major bleeding (n = 1) 
♦ Acute respiratory failure (n = 8) 
♦ Acute renal failure (n = 10) 
♦ Other serious infection (n = 2) 
♦ Shock (n = 32) 
♦ Enteritis NCI grade 3-4 (n = 7) 
♦ Mucositis NCI grade 3-4 (n = 4) 
♦ Other serious complications (n = 2) 
♦ Complications (n = 55) 
♦ Death (n = 8) 
Eligible episodes of
seemingly stable FN
(n = 296)     
USH registry
(n = 389)  
Figure 1. Flow diagram of the FINITE and USH series.
Points
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Chronic cardiovascular
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Figure 2. The CISNE nomogram. COPD¼ chronic obstructive pulmonary disease; ECOG PS¼Eastern Cooperative Oncology Group Performance
Status; NCI¼National Cancer Institute.
Prognosis assessment of febrile neutropenia BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.118 1195
instance, infection-related mortality was significantly lower in
seemingly stable patients in comparison with clinically unstable
subjects (3% vs 18%). However, the absence of severity criteria at
the onset does not fully rule out the possibility that the neutropenic
patient will develop serious complications, which occurred in 18%
of the patients deemed stable and even in 5.5% of those who
received direct or early discharged in the USH cohort.
In light of the aforementioned, we believe that a CISNE-based
nomogram can contribute to improve exclusion criteria for
management in these patients, as well as their classification, or
decision-making regarding oral or outpatient treatment.
The nomogram has several limitations that must be indicated to
optimise its use. While the model’s functioning was robust in a
subsequent update and its explanatory covariables therefore appear
to be appropriate in different contexts, one must always be mindful
of the possibility of uncommon risk factors, for example, cirrhosis,
malnutrition, chronic renal disease, or other pathologies or
situations. Although patients with lymphomas were included,
there were so few cases (n¼ 21) as to advise caution when
dealing with this population. The USH registry’s sample size
depended on patient volume, but the series contains B91% of
the events generally recommended for studies such as this one
(Peduzzi et al, 1996). Similarly, it is possible that the nomogram’s
discriminatory ability might be enhanced in the future by
incorporating new variables. Given their extraordinary variability,
it is important that we attempt to integrate patients’ specific
infection and oncological status. Nevertheless, these six variables
appear to be germane and discriminatory in the three series
analyzed. The model appears to be well calibrated across the
spectrum of severity despite which a slight underestimation of risk
was seen in the range between 20 and 40% of predicted
probabilities of the USH cohort. Although the eligibility criteria
for oral, outpatient management in the USH registry were similar
to those of the Infectious Disease Society of America (IDSA)
clinical practice guidelines (Freifeld et al, 2011), the decision as to
where to treat fell ultimately to the treating physician, who had to
factor in each patient’s particular risk factors, or other family,
psychological, or social aspects. The USH series also suggests that a
percentage of serious complications can be detected only by
increasing the screening period beyond 3 h (e.g. by in-hospital
observation for 6–24 h).
Finally, how the CISNE model would be used within the current
classification systems recommended by clinical guidelines must be
elucidated, as well as the differences with respect to other existing
models, such as the Talcott and Multinational Association for
Supportive Care in Cancer (MASCC) score (Talcott et al, 1992;
Klastersky et al, 2000). At present, the MASCC score is the most
widely validated and recommended to identify low-risk patients,
although never as a stand-alone selection method, but rather in
combination with exclusion criteria similar to the ones proposed in
this article (Flowers et al, 2013). However, our group has
demonstrated that the CISNE score is better able to discriminate
than the MASCC model when used in apparently stable patients
with solid tumours: areas under the receiver operating character-
istic curves 0.721 (95% CI, 0.669–0.768) for MASCC and 0.868
(95% CI, 0.827–0.903) for CISNE (P¼ 0.002) (Carmona-Bayonas
et al, 2015).
Several methodological issues hinder the applicability of the
MASCC model in daily clinical practice. Most notable among them
are that the heaviest weighted predictor, hypotension, is also the
most common outcome; that a relevant percentage had acute
leukaemia or bone marrow transplant, limiting its application to
patients with solid tumours; or that many patients were initially
haemodynamically unstable and could therefore never be classified
as low risk, despite their MASCC score.
The most obvious advantage of the CISNE model over the
previously proposed ones is that the two-step triage process
improves patient safety, reinforcing decision-making without
added complexity. CISNE seeks to decrease the uncertainty linked
to the diminished inflammatory response due to immunosuppres-
sion, which undermines the clinician’s ability to detect
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Figure 3. Calibration plot showing predicted probability vs actual
(observed) frequencies of serious complications in clinically stable
patients from the FINITE study (n¼1133). (Bootstrap procedure with
2000 repetitions; mean absolute error¼0.008; mean squared
error¼ 0.00021; 0.9 quantile of absolute error¼0.014. Distribution of
predicted risks of patients is shown at top of the figure.)
Table 3. Distribution of risk classes and outcomes derived
from the FINITE and USH seriesa
% (95% confidence interval)
FINITE series,
n¼1133 (%)
USH registry,
n¼296 (%)
Distribution of nomogram points
0–57 49.6 (46.7–52.6) 55.1 (49.3–60.6)
58–115 19.2 (17.0–21.6) 18.5 (14.5–23.4)
116–175 17.3 (15.2–19.6) 15.5 (11.8–20.1)
176–231 9.7 (8.1–11.5) 8.1 (5.5–11.7)
X232 4.1 (3.1–5.3) 2.7 (1.3–5.2)
Complications by nomogram points
0–57 2.3 (1.3–3.9) 4.2 (2.0–8.5)
58–115 9.6 (6.3–14.2) 20 (11.5–32.3)
116–175 17 (13.1–23.8) 37.8 (26.3–53.5)
176–231 47.2 (38.1–56.5) 50 (31.4–68.5)
X232 67.3 (52.9–79.1) 100 (67–100)
Mortality by nomogram points
0–57 0.1 (0.03–1.0) 0.6 (0.1–3.3)
58–115 2.2 (0.9–5.2) 1.8 (0.3–9.6)
116–175 2.5 (1.1–5.8) 2.2 (3.9–11.5)
176–231 4.5 (1.9–10.2) 8.3 (2.3–25.8)
X232 8.7 (3.4–20.3) 37.5 (13.6–69.4)
Abbreviations: FINITE¼Evaluacio´n de Factores Prono´sticos en Fiebre Neutrope´nica,
Tumour So´lido y Episodios Estables; USH¼University of Salamanca Hospital.
aIn the FINITE series, Youden’s (J) index was X116 points (high risk). The cutoffs used to
create the five prognostic categories are multiples of half of Youden’s index.
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Figure 4. Calibration plot showing predicted probability vs actual
(observed) proportions of serious complications in clinically stable
patients from the USH registry (n¼296). (Bootstrap procedure with
2000 repetitions; mean absolute error¼ 0.036; mean squared
error¼0.00291; 0.9 quantile of absolute error¼ 0.111. Distribution of
predicted risks of patients is shown at top of the figure.)
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complications early on. As a final point, CISNE is a safe method
because, unlike others, its prime purpose is not to release patients
early, but just the opposite – to keep them from occurring until the
apparent stability has been confirmed as real after an appropriate
time of in-hospital observation. Therefore, the results of our study
are mainly applicable to avoid early discharge of patients with
cancer beginning in-patient therapy. In light of our data, we
suggest that patients experiencing seemingly stable episodes with a
CISNE nomogram score X116 points (equivalent to a risk of
serious complications X13%) should not be sent home until they
have proven to be truly stable and blood cultures have been
examined. On the contrary, we emphasise that this nomogram
should not be used so much to select low-risk patients for direct
outpatient treatment. Nevertheless, well-conducted clinical trials
are required to endorse that this prognostic classification can be
safely and efficaciously associated with therapeutic classes.
In short, we report a nomogram to predict complications in
seemingly stable patients with solid tumour who present FN and
who commence in-patient treatment. This tool has been developed
in two different series that, together, comprise more than 1400
eligible patients and subsequently validated using an external
database. The nomogram can therefore be useful for individualis-
ing patient care in terms of treatment and place, in addition to
interpreting other series and future studies in this field.
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